EUVIMEDEUVIMED entdecken
Open Access

The protective effects of Irbesartan in cognitive impairment in hypertension

Shengyun Hao, Qian He, Yuan Yuan, Qiong Mu

Aging · 2024

DOI: 10.18632/aging.205589 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aging, 2024. Verfasst von Shengyun Hao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medical, Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China. Hauptthemen laut MEDLINE: Hypertension, Cognitive Dysfunction. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vascular cognitive impairment (VCI) is claimed as the second most common type of dementia after Alzheimer's disease (AD), in which hypertension is a critical inducer. Currently, hypertension-induced cognitive impairment lacks clinical treatments. Irbesartan is a long-acting angiotensin receptor antagonist with promising antihypertensive properties. Our research will focus on the potential function of Irbesartan on hypertension-induced cognitive impairment. Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats were orally dosed with normal saline or 20 mg/kg/day Irbesartan for 14 consecutive days, with 4 groups divided shown as below: WKY, Irbesartan, SHR, SHR+ Irbesartan. Firstly, the markedly increased systolic blood pressure observed in SHR rats was signally repressed by Irbesartan on Day 7 and 14 post-dosing. Moreover, notably decreased time of exploring the novel object in the object recognition task (ORT) test, elevated escape latency, and reduced time in the target quadrant in the Morris water maze (MWM) test were observed in SHR rats, which were prominently reversed by Irbesartan. Furthermore, the declined superoxide dismutase (SOD) activity, elevated malondialdehyde (MDA) level, increased cyclin-dependent kinase-5 (CDK5) activity, and enhanced protein level of p35/p25, p-Tau (pSer214)/Tau46, and brain-derived neurotrophic factor (BDNF) were memorably rescued by Irbesartan. Lastly, the activity of cAMP/cAMP response element binding protein (CREB) signaling in the hippocampus of SHR rats was markedly repressed, accompanied by an upregulation of phosphodiesterase 4B (PDE4B), which was observably rescued by Irbesartan. Collectively, Irbesartan protected against the hypertension-induced cognitive impairment in SHR rats by regulating the cAMP/CREB signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionCognitive DysfunctionRatsAnimalsIrbesartanRats, Inbred SHRRats, Inbred WKYBlood PressureBiphenyl CompoundsTetrazoles

Stichwörter der Autor:innen

IrbesartancAMP/CREBcognitive impairmenthypertensionvascular cognitive impairment (VCI)

Substanzen

IrbesartanBiphenyl CompoundsTetrazoles

Autor:innen und Institutionen

  • Department of General Medical, Affiliated Hospital of Guizhou Medical University, Guiyang 550001, China.

Zitieren

APA

Hao, S., He, Q., Yuan, Y., & Mu, Q. (2024). The protective effects of Irbesartan in cognitive impairment in hypertension. Aging. https://doi.org/10.18632/aging.205589

Vancouver

Hao S, He Q, Yuan Y, Mu Q. The protective effects of Irbesartan in cognitive impairment in hypertension. Aging. 2024. doi:10.18632/aging.205589

BibTeX
@article{Hao2024,
  author = {Hao, Shengyun and He, Qian and Yuan, Yuan and Mu, Qiong},
  title = {The protective effects of Irbesartan in cognitive impairment in hypertension},
  journal = {Aging},
  year = {2024},
  doi = {10.18632/aging.205589}
}
Kostenlos starten →